• Insulin drug pricing. (Lobbyists did not engage in lobbying activity on this issue during the reporting period)
• FY 21 funding for National Institute of Diabetes and Digestive and Kidney Diseases; CDC Diabetes program; National Diabetes Prevention Program; FY 20 diabetes funding in Labor, Health, & Human service & Defense appropriations.

Duration: November 12, 2009 to December 31, 2019

General Issues: Health Issues, Budget/Appropriations, Medicare/Medicaid

Spending: about $1,045,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2009: Office of Management & Budget (OMB), U.S. Senate, House of Representatives, Natl Institutes of Health (NIH), White House Office, Natl Institutes of Health (NIH),, U.S. Senate,, Centers For Disease Control & Prevention (CDC)